Raphael Pharmaceutical Inc. (RAPH)
Raphael Pharmaceutical Inc. operates as a biopharmaceutical firm, concentrating its efforts on discovering and clinically developing novel therapeutic solutions. These treatments primarily leverage cannabinoids and are designed to enhance patients' quality of life. Currently, the company's leading investigational drug candidate is being advanced for the management of rheumatoid arthritis. Furthermore, Raphael Pharma plans to broaden its pipeline to include more cannabinoid-based medicines aimed at various cancer types and other autoimmune conditions. The company's corporate headquarters are situated in Tel Aviv-Jaffa, Israel.
Sector: Medicinal Chemicals & Botanical Products
Industry: Drug Manufacturers - Specialty & Generic
Raphael Pharmaceutical Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
ILRaphael Pharmaceutical Inc. operates as a biopharmaceutical firm, concentrating its efforts on discovering and clinically developing novel therapeutic solutions. These treatments primarily leverage cannabinoids and are designed to enhance patients' quality of life. Currently, the company's leading investigational drug candidate is being advanced for the management of rheumatoid arthritis. Furthermore, Raphael Pharma plans to broaden its pipeline to include more cannabinoid-based medicines aimed at various cancer types and other autoimmune conditions.
The company's corporate headquarters are situated in Tel Aviv-Jaffa, Israel.
Leadership
Employees
--
Country
IL
Sector
Healthcare
Website
raphaelpharmaceutical.com
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
 Louria Hayon Igal | Chief Technology Officer | In-the-Money Exercise | 350.0K | $3.5K | Nov 20, 2025 |
| Louria Hayon Igal | Chief Technology Officer | In-the-Money Exercise | 350.0K | -- | Nov 20, 2025 |
 Eliya Yehuda | Director | Grant/Award | 200.0K | -- | Mar 10, 2025 |
 Dhadha Ajay Kumar | Director | Grant/Award | 350.0K | -- | Mar 5, 2025 |
| Dhadha Ajay Kumar | Director | Grant/Award | 250.0K | -- | Mar 5, 2025 |
 Pilo Shlomo | Chief Executive Officer | Grant/Award | 200.0K | $100.0K | Mar 2, 2025 |
| Name | Shares | % | Source |
|---|---|---|---|
 Pilo Shlomo Chief Executive Officer, Director, 10% Owner | 4.0M | -- | FORM 4 |
 Louria Hayon Igal Chief Technology Officer | 1.3M | -- | FORM 4 |
 Dhadha Ajay Kumar Director | 351.7K | -- | FORM 4 |
Insiders
- Louria Hayon IgalChief Technology Officer
- Eliya YehudaDirector
- Dhadha Ajay KumarDirector
- Pilo ShlomoChief Executive Officer
IL30d Avg
100
60d Avg
100
90d Avg
100